Predicting Tumor Mutational Burden from UHF-Dielectrophoresis Crossover Frequency
Héloïse DaveratiD, Nina BlascoiD, Sandrine RobertiD, Arnaud PothieriD, Amandine M.F. RoviniiD, Marie BoutaudiD, Charlotte JemferiD, Claire Dalmay AiD, Fabrice LallouéiD, Karine DurandiD, Thomas NavesiD
Abstract
Tumor Mutational Burden (TMB) has emerged as a crucial biomarker to guide patient eligibility for immunotherapy. However, whole exome sequencing, the gold-standard method for TMB measurement, remains limited in accessibility due to its high costs, operational complexity, and lengthy processing times. To address these limitations, we investigated whether Ultra-High-Frequency (UHF) technology could serve as a novel approach to assess TMB by analyzing the crossover frequencies or electromagnetic signature (EMS) of cancer cells on a lab-on-a-chip biosensor, integrating microfluidics and dielectrophoresis. In a panel of 12 cancer cell lines with varying TMB levels, we observed that EMS showed an upward shift correlating with higher TMB, particularly in solid tumor cell lines. This finding suggests a potential relationship between TMB and EMS. To further explore this hypothesis, we artificially increased mutation levels by treating cells with the highly mutagenic compound N-ethyl-N-nitrosourea (ENU). Results showed that EMS captured significant TMB variations in ENU-treated cells with enhanced proliferative capacity compared to their parental counterparts. These results underscore the importance of matched control samples for reliable EMS measurements. Altogether, our findings highlight the potential of EMS to detect TMB variations associated with proliferative activity, a key hallmark of cancer cells, thereby enabling a more precise stratification of cancer cells. HighlightsO_LIWe propose a new biosensor to improve patient stratification for ICI eligibility C_LIO_LIHigh frequency fields and dielectric spectroscopy can estimate TMB in cancer cells C_LIO_LISignificant changes in UHF-DEP signatures correlate with varying TMB levels C_LIO_LIUHF-DEP provides a cheap, rapid and label-free method to predict ICI response C_LIO_LIOffers an innovative and complementary marker to conventional diagnostic approaches C_LI Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=92 SRC="FIGDIR/small/622085v1_ufig1.gif" ALT="Figure 1"> View larger version (22K): org.highwire.dtl.DTLVardef@703983org.highwire.dtl.DTLVardef@1cfdf46org.highwire.dtl.DTLVardef@4b9285org.highwire.dtl.DTLVardef@1809255_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ecTMB: a robust method to estimate and classify tumor mutational burden
Lijing Yao, Yao Fu, … Hugo Y. K. Lam·Scientific ReportsPeer-reviewed·Mar 18, 2020
- Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types
- Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small Cell Lung Cancer
Chang Han, Ariella Sasson, … Joseph D. Szustakowski·Molecular Diagnosis & TherapyPeer-reviewed·Jun 27, 2019
- Predicting tumour mutational burden from histopathological images using multiscale deep learning
Mika Sarkin Jain, Tarik F. Massoud·Nature Machine IntelligencePeer-reviewed·Jun 15, 2020
- Prevalence and mutational determinants of high tumor mutation burden in breast cancer
Romualdo Barroso‐Sousa, Esha Jain, … Nikhil Wagle·Annals of OncologyPeer-reviewed·Jan 9, 2020
- Revisiting Tumor Mutational Burden Cutoff: Multi-Study Replicability in Immunotherapy
Iman Jaljuli, Karissa A. Whiting, … Li‐Xuan Qin·bioRxiv·Jan 2, 2025